F. Lavelle

Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience.

M. Bissery, G. Nohynek, G. Sanderink, 1995, Anti-cancer drugs.

Preclinical evaluation of docetaxel (Taxotere).

P. Vrignaud, M. Bissery, J. Riou, 1995, Seminars in oncology.

Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation.

G. Riou, S. Prost, J. Riou, 1993, Biochemical pharmacology.

Telomerase: a therapeutic target for the third millennium?

J. Riou, A. Laoui, P. Mailliet, 2000, Critical reviews in oncology/hematology.

Mode of action of the antitumor compound girodazole (RP 49532A, NSC 627434).

B. Rabault, A. Zerial, F. Lavelle, 1992, Biochemical pharmacology.

Preclinical evaluation of CPT-11 and its active metabolite SN-38.

F. Roquet, M. Bissery, J. Riou, 1996, Seminars in oncology.